Literature DB >> 342360

Double-blind controlled trial of amylopectin sulphate (Depepsen) in the symptomatic treatment of duodenal ulcer.

J H Baron, R J Gribble, D J Holdstock, J J Misiewicz.   

Abstract

In a double-blind controlled trial amylopectin sulphate (Depepsen) had no significant advantage over placebo in the symptomatic treatment of duodenal ulcer.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 342360      PMCID： PMC1411654          DOI： 10.1136/gut.18.9.723

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  5 in total

1.  A controlled trial of antacid, propantheline and amylopectin sulfate in duodenal ulcer.

Authors:  D C Sun
Journal:  Am J Gastroenterol       Date:  1973-11       Impact factor: 10.864

2.  A controlled study on the use of propantheline and amylopectin sulfate (SN-263) for recurrences in duodenal ulcer.

Authors:  D C Sun; M L Ryan
Journal:  Gastroenterology       Date:  1970-06       Impact factor: 22.682

3.  Specific inhibition of gastric pepsin in the treatment of gastric ulcer.

Authors:  D S Zimmon; G Miller; G Cox; M A Tesler
Journal:  Gastroenterology       Date:  1969-01       Impact factor: 22.682

4.  Effect of depepsen in the treatment of peptic ulcer.

Authors:  D Cayer; J M Ruffin
Journal:  Ann N Y Acad Sci       Date:  1967-01-26       Impact factor: 5.691

5.  A trial of amylopectin sulfate (SN-263) and propantheline bromide in the long term treatment of chronic duodenal ulcer.

Authors:  J B Cocking
Journal:  Gastroenterology       Date:  1972-01       Impact factor: 22.682
  5 in total
  7 in total

Review 1.  There is more to healing ulcers than suppressing acid.

Authors:  D G Colin-Jones
Journal:  Gut       Date:  1986-05       Impact factor: 23.059

2.  New drugs for peptic ulcer.

Authors: 
Journal:  Br Med J       Date:  1980-07-12

3.  The controlled trial.

Authors:  R Doll
Journal:  Postgrad Med J       Date:  1984-11       Impact factor: 2.401

Review 4.  Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

5.  Double-blind randomised clinical trial of a pepsin-inhibitory pentapeptide (pepstatin) in the treatment of duodenal ulcer.

Authors:  O Bonnevie; L B Svendsen; J Holst-Christensen; T S Johansen; J Søltoft; P M Christiansen
Journal:  Gut       Date:  1979-07       Impact factor: 23.059

6.  Prevention of acute gastric erosions in the rat by novel semi-synthetic amphipathic analogues of pepstatin.

Authors:  S P Huddy; G Patel; G C Heywood; B M Austen; J Hermon-Taylor
Journal:  Gut       Date:  1988-11       Impact factor: 23.059

7.  Reflux revisited: advancing the role of pepsin.

Authors:  Karna Dev Bardhan; Vicki Strugala; Peter W Dettmar
Journal:  Int J Otolaryngol       Date:  2011-11-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.